Decreased expression of apelin in placentas from severe pre-eclampsia patients

Hypertension in Pregnancy

Volumn 32, Issue 4, 2013, Pages 410-421

  Inuzuka, Hiromi ^a   Nishizawa, Haruki ^a   Inagaki, Ayaka ^a   Suzuki, Machiko ^a   Ota, Sayuri ^a   Miyamura, Hironori ^a   Miyazaki, Jun ^a   Sekiya, Takao ^a   Kurahashi, Hiroki ^a   Udagawa, Yasuhiro ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Angiogenic factor; Apelin; APJ; Placenta; Pre eclampsia

Indexed keywords

APELIN; APELIN RECEPTOR; MESSENGER RNA;

ADULT; ANGIOGENESIS; ARTICLE; CELL LINEAGE; CELL MEMBRANE; CHORION VILLUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NIDATION; NUCLEOTIDE SEQUENCE; PLACENTA; PREECLAMPSIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNCYTIOTROPHOBLAST; TROPHOBLAST;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84884797435     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641955.2013.813535     Document Type: Article

References (41)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99
2. Hall DR, Odendaal HJ, Steyn DW, Grove D. Expectant management of early onset, severe pre-eclampsia: Maternal outcome. BJOG 2000;107:1252-7
3. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357:53-6
4. Woodage T, Venter JC, Broder S. Application of the human genome to obstetrics and gynecology. Clin Obstet Gynecol 2002;45:711-32
5. Cross JC. The genetics of pre-eclampsia: A feto-placental or maternal problem? Clin Genet 2003;64:96-103
6. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58
7. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-9
8. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83
9. Levine RJ, Lam C, Qian C, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355: 992-1005
10. Barnes G, Japp AG, Newby DE. Translational promise of the apelin-APJ system. Heart 2010;96:1011-16
11. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-6
12. Hosoya M, Kawamata Y, Fukusumi S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000;275:21061-7
13. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000;74:34-41
14. De Falco M, De Luca L, Onori N, et al. Apelin expression in normal human tissues. In Vivo 2002;16:333-6
15. Kasai A, Shintani N, Oda M, et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004;325:395-400
16. Cox CM, D'Agostino SL, Miller MK, et al. Apelin, the ligand for the endothelial Gprotein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 2006;296:177-89
17. Kidoya H, Ueno M, Yamada Y, et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008;27:522-34
18. Nishizawa H, Pryor-Koishi K, Kato T, et al. Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. Placenta 2007;28:487-97
19. Nishizawa H, Ota S, Suzuki M, et al. Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod Biol Endocrinol 2011;9:107
20. Van Mieghem T, van Bree R, Van Herck E, et al. Maternal apelin physiology during rat pregnancy: The role of the placenta. Placenta 2010;31:725-30
21. Cobellis L, De Falco M, Mastrogiacomo A, et al. Modulation of apelin and APJ receptor in normal and preeclampsia-complicated placentas. Histol Histopathol 2007;22:1-8
22. Liao YM, Qiao FY. Expression of Apelin in placentas of patients with hypertensive disorders complicating pregnancy. Zhonghua Fu Chan Ke Za Zhi 2007;42:382-5
23. Simsek Y, Celik O, Yilmaz E, et al. Serum levels of apelin, salusin-Alpha and salusin-beta in normal pregnancy and preeclampsia. J Matern Fetal Neonatal Med 2012;25:1705-8
24. Bortoff KD, Qiu C, Runyon S, et al. Decreased maternal plasma apelin concentrations in preeclampsia. Hypertens Pregnancy 2012;31:398-404
25. ACOG Committee on Obstetric Practice: ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Int J Gynaecol Obstet 2002;77:67-75
26. van Diest PJ, van Dam P, Henzen-Logmans SC, et al. A scoring system for immunohistochemical staining: Consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol 1997;50:801-4
27. Atluri P, Morine KJ, Liao GP, et al. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett 2007;12: 127-38
28. Masri B, Knibiehler B, Audigier Y. Apelin signalling: A promising pathway from cloning to pharmacology. Cell Signal 2005;17:415-26
29. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: Implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003;69:1-7
30. Levy R, Nelson DM. To be, or not to be, that is the question. Apoptosis in human trophoblast. Placenta 2000;21:1-13
31. Heazell AE, Crocker IP. Live and let die-regulation of villous trophoblast apoptosis in normal and abnormal pregnancies. Placenta 2008;29:772-83
32. Kidoya H, Naito H, Takakura N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood 2010;115:3166-74
33. Kasai A, Ishimaru Y, Kinjo T, et al. Apelin is a crucial factor for hypoxia-induced retinal angiogenesis. Arterioscler Thromb Vasc Biol 2010;30:2182-7
34. Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv 2011;66:497-506
35. Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001;99:87-92
36. Briana DD, Malamitsi-Puchner A. Reviews: Adipocytokines in normal and complicated pregnancies. Reprod Sci 2009;16:921-37
37. Page NM. The endocrinology of pre-eclampsia. Clin Endocrinol 2002;57:413-23
38. Anim-Nyame N, Sooranna SR, Steer PJ, Johnson MR. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and preeclampsia. Hum Reprod 2000;15:2033-6
39. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005;107:198-211
40. Lee DK, George SR, O'Dowd BF. Unravelling the roles of the apelin system: Prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 2006;27:190-4
41. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011;108:1451-5